Measuring cognition in advanced Alzheimer's disease for clinical trials

Journal of Neural Transmission, Supplement

Volumn , Issue 62, 2002, Pages 135-148

  Schmitt, F A ^a,b,c   Cragar, D ^c   Ashford, J W ^a,c   Reisberg, B ^d   Ferris, S ^d   Mobius H J ^e   Stoffler A ^e  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; MEMANTINE;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; DEPTH PERCEPTION; DISEASE COURSE; HUMAN; MEASUREMENT; MEMORY; PRIORITY JOURNAL; RATING SCALE; AGED; METHODOLOGY; REVIEW;

AGED; ALZHEIMER DISEASE; CLINICAL TRIALS; COGNITION; COGNITION DISORDERS; HUMANS;

EID: 0036047651     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6139-5_14     Document Type: Conference Paper

References (51)

1. Albert M, Cohen C (1992) The test for severe impairment: an instrument for the assessment of patients with severe cognitive dysfunction. J Am Geriatr Soc 40: 449-453
2. Auer SR, Reisberg B (1996) Reliability of the modified ordinal scales of psychological development: a cognitive assessment battery for severe dementia. Int Psychogeriatr 8: 225-231
3. Auer SR, Sclan SG, Yaffee RA, Reisberg B (1994) The neglected half of Alzheimer's disease: cognitive and functional concomitants of severe dementia. J Am Geriatr Soc 42: 1266-1272
4. Ashford JW, Schmitt FA (2001) Modeling the time-course of Alzheimer dementia. Curr Psychiatr Reports 3: 20-28
5. Ashford JW, Schmitt FA, Kumar V (1998) Diagnosis of Alzheimer's disease. Psychiatr Ann 26: 262-268
6. Barner EL, Gray SL (1998) Donepezil use in Alzheimer disease. Ann Pharmacother 32: 70-77
7. Burns A, Jacoby R, Levy R (1991) Progression of cognitive impairment in Alzheimer's disease. J Am Geriatr Soc 39: 39-45
8. Cummings JL, Benson DF (1992) Psychological dysfunction accompanying subcortical dementias. Annu Rev Med 3: 953-961
9. Doody RS, Dunn JK, Clark CM, Farlow M, Foster NL, Liao T, Gonzales N, Lai E, Massman P (2001) Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord 12: 295-300
10. Edland SD (2000) Blomqvist revisited: how and when to test the relationship between level and longitudinal rate of change. Stat Med 19: 1441-1452
11. Farlow M, Anand R, Messina J Jr, Hartman R, Veach J (2000) A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 44: 236-241
12. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E (2001) A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57: 613-620
13. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198
14. Galasko DR, Schmitt FA, Jin S, Saxton J, Bennett D, Sano M, Ferris SH (2000) Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer's disease. Neurobiol Aging 21(1S): 168
15. Guy W. 028 CGI (1976) Clinical global impressions. In: Assessment manual for psychopharmacology, rev edn. National Institute of Mental Health, Rockville, Maryland, pp 217-222
16. Harrell LE, Marson D, Chatterjee A, Parrish JA (2000) The severe mini-mental state examination: a new neuropsychologic instrument for the bedside assessment of severely impaired patients with Alzheimer's disease. Alzheimer Dis Assoc Disord 14:168-175
17. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140: 566-572
18. Jarvik LF, Berg L, Bartus R, Heston L, Leith N, Phelps C, Shader R, Whitehouse P (1990) Clinical drug trials in Alzheimer's disease: what are some of the issues? Alzheimer Dis Assoc Disord 4: 193-202
19. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI (1994) A 30-week randomized controlled trial of high dose tacrine in patients with Alzheimer's disease. JAMA 271: 985-991
20. Mackell JA, Ferris SH, Mohs R, Schneider L, Galasko D, Whitehouse P, et al (1997) Multicenter evaluation of new instruments for Alzheimer's disease clinical trials: summary of results. Alzheimer Dis Assoc Disord 11[Suppl 2]: 2-7
21. Mattis S (1988) Dementia rating scale professional manual. Psychological Assessment Resources Inc, Odessa, Florida
22. Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt FA (2000) Modelling mini mental state examination changes in Alzheimer's disease. Stat Med 19: 1607-1616
23. Mesulam MM (1996) The systems-level organization of cholinergic innervation in the human cerebral cortex and its alterations in Alzheimer's disease. Prog Brain Res 109: 285-297
24. Mohs RC (1996) Comprehensive and neuropsychologic evaluations. The Alzheimer's disease assessment scale. Int Psychogeriatr 8: 195-203
25. Mohs RC, Cohen L (1988) Alzheimer's disease assessment scale (ADAS). Psychopharmacol Bull 24: 627-628
26. Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B (1998) Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 50: 1222-1230
27. Panisset M, Roudier M, Saxton J, Boller F (1994) Severe impairment battery - a neuropsychological test for severely demented patients. Arch Neurol 51: 41-45
28. Peavy GM, Salmon DP, Rice VA, Galasko D, Samuel W, Taylor KI, Ernesto C, Butters N, Thal L (1996) Neuropsychological assessment of severely demeted elderly: the severe cognitive impairment profile. Arch Neurol 53: 367-372
29. Raskind MA, Peskind ER, Wessel T, Yuan W (2000) Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54: 2261-2268
30. Reisberg B (1988) Functional assessment staging (FAST). Psychopharmacol Bull 24: 653-659
31. Reisberg B, Ferris SH, de Leon MJ, Crook T (1982) The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 139: 1136-1139
32. Reisberg B, Windscheif U, Ferris SH, Hingorani VH, Stöffler A, Möbius HJ (2000) Memantine in moderately severe to severe Alzheimer's disease (AD): results of a placebo-controlled 6-month trial. Neurobiol Aging 21(1S): S275
33. Rogers SL, Friedhoff LT (1996) The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a U.S. multicentre, randomized, double-blind, placebo controlled trial. Dementia 7: 293-303
34. Rogers SL, Friedhoff LT (1998) Long term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 8: 67-75
35. Rogers SL, Doody RS, Mobs RC, Friedhoff LT (1998a) Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 158: 1021-1031
36. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998b) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50: 136-145
37. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141: 1356-1364
38. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M (1999) Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 318: 633-638
39. Sano M, Growdon J, Klauber M, Erneston C, Schafer P, Woodbury P, Grundman M, Thal L (1995) Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicenter clinical trial of selegiline and alpha tocopherol. Neurology 45[Suppl 4]: A289
40. Sano M, Ernesto C, Klauber M, Schafer K, Woodbury P, Grundman M, Thal L, Alzheimer's Disease Cooperative Study Group (1996) Using the ADAS to assess change among moderately and severely impaired AD patients. J Int Neuropsychol Soc 2: 13
41. Sano M, Growdon J, Thomas C, Ernesto K, Schafer K, Woodbury P, Grundman M, Thal L (1996) Evaluation of efficacy measures in clinical trials for Alzheimer's disease: does psychometric test performance predict clinically relevant outcomes? Neurology 46: A218
42. Saxton J, McGonigle-Gibson KL, Swihart AA, Miller VJ, Boller F (1990) Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery. J Consult Clin Psychol 2: 298-303
43. Saxton J, Swihart A, McGonigle-Gibson KL, Miller VJ, Boller F (1990) Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery. Psychol Assess 2: 298-303
44. Saxton J, McGonigle KL, Swihart AA, Boller F (1993) The severe impairment battery manual. Thames Valley Test Company, Bury St. Edmunds
45. Saxton J, McGonigle KL, Swihart AA, Boller F (1993) The Severe Impairment Battery. The University of Pittsburgh of the Commonwealth System of Higher Education (eds) Thames Valley Test Company, Suffolk, pp 1-16
46. Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, Ferris SH, Mackell JA, Schafer K, Thal LJ (1997) The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimers Dis Assoc Disord 11[Suppl 2]: 51-56
47. Sclan SG, Reisberg B (1992) Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int Psychoger 4[Suppl 1]: 55-69
48. Volicer L, Hurley AC, Lathi DC, Kowall NW (1994) Measurement of severity in advanced Alzheimer's disease. J Gerontol 49: M223-M226
49. Whitehouse PJ (1987) Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson's disease and Alzheimer's disease. Adv Neurol 45: 393-397
50. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR (1982) Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215: 1237-1239
51. Wild KV, Kaye JA (1998) The rate of progression of Alzheimer's disease in the later stages: evidence from the severe impairment battery. J Int Neuropsychol Soc 4: 512-516